Latest Myelofibrosis Stories
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp.
- PharmaEssentia and AOP Orphan announce completion of recruitment of the pivotal European Phase III trial PROUD-PV (www.proud-pv.com) to support global marketing of P1101 (Ropeginterferon alfa-2b).
Trial Meets Primary Endpoint in Intent-to-Treat Population SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, Jan. 8, 2015 /PRNewswire/ -- CTI BioPharma Corp.
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- SEATTLE, Dec.
FLINT, Mich., Dec. 5, 2014 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced that the U.S.
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
To mark National Sickle Cell Month which occurs every September, the Editorial Board of Living with a Disability magazine has published an important new article that sheds light on hematological
SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S.
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.